Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | FABP7 | O15540 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31470993 | 1.00 | CASP3 (0.63) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL30604630 | 1.00 | CASP3 (0.63) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL14265313 | 0.94 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL12627627 | 0.94 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL799712 | 0.94 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL2950163 | 0.93 | CASP3 (0.59) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15569571 | 0.93 | CASP3 (0.59) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL7163906 | 0.93 | CASP3 (0.59) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL28777598 | 0.92 | CASP3 (0.58) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL28777600 | 0.92 | CASP3 (0.58) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023179723-A1 | CLEAVABLE FRAGMENT DIRECTED BY AFFINITY FRAGMENT, DESIGN AND SYNTHESIS THEREOF, AND USE THEREOF IN PREPARATION OF SITE-DIRECTED DRUG CONJUGATE | 中国科学院上海药物研究所 | 2023-09-28 | — | — | WO | disclosed |
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | MC SAF (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-4181964-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | Mc SAF (FR) | 2023-05-24 | — | — | EP | disclosed |
| EP-3099692-B9 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3099692-B9 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10391182-B2 | Bifunctional cytotoxic agents | PFIZER INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10391182-B2 | Bifunctional cytotoxic agents | PFIZER INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3521292-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521292-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3099692-B1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277678-A1 | COMPOUNDS CAPABLE OF BINDING TO PROTEINS AND CONJUGATES OBTAINED FROM THESE COMPOUNDS | SHBG, SERPINA6, F13B | CASP3 4329/4885KMT2A 4179/4885EPHX2 2309/4885 |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PAICS, CYTH3, CYTH2 | CASP3 195/4885KMT2A 2521/4885EPHX2 701/4885 |
| US-10391182-B2 | Bifunctional cytotoxic agents | PAICS, CYTH3, CYTH2 | CASP3 195/4885KMT2A 2521/4885EPHX2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.